Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Molecules (Basel, Switzerland)
|
February 11, 2023
Survivin Small Molecules Inhibitors: Recent Advances and Challenges
Najah Albadari, Wei Li
Expert Opinion on Drug Discovery
|
May 10, 2019
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Najah Albadari, Shanshan Deng, Wei Li
Frontiers in Pharmacology
|
January 25, 2024
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
Najah Albadari, Yang Xie, Wei Li
Frontiers in Oncology
|
December 12, 2022
MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
Tao Liu, Lubing Gu, Zhongzhi Wu, et al.
Cancer Letters
|
July 25, 2024
An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues
Tao Liu, Lubing Gu, Anna Mui, et al.
European Journal of Medicinal Chemistry
|
May 2, 2023
Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
Najah Albadari, Yang Xie, Tao Liu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
May 21, 2025
Synthesis, <i>in vitro</i> and <i>in silico</i> studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity <i>via</i> G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II
Mohammed Khaled Bin Break, Siddique Akber Ansari, Ahmed A Katamesh, et al.
Computational Biology and Chemistry
|
June 20, 2026
Structure-based discovery of PARP15 inhibitors with enhanced binding energetics and stability via quantum refinement for targeted breast cancer therapy
Najah Albadari, Ahmed Alafnan, Mohammed A Almuhayfir, et al.
European Journal of Medicinal Chemistry
|
August 9, 2021
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold
Najah Albadari, Shanshan Deng, Hao Chen, et al.
Genes & Diseases
|
January 13, 2025
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Wei Wang, Yi Du, Sayantap Datta, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Molecules (Basel, Switzerland)
|
February 11, 2023
Survivin Small Molecules Inhibitors: Recent Advances and Challenges
Najah Albadari, Wei Li
Expert Opinion on Drug Discovery
|
May 10, 2019
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Najah Albadari, Shanshan Deng, Wei Li
Frontiers in Pharmacology
|
January 25, 2024
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
Najah Albadari, Yang Xie, Wei Li
Frontiers in Oncology
|
December 12, 2022
MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
Tao Liu, Lubing Gu, Zhongzhi Wu, et al.
Cancer Letters
|
July 25, 2024
An MDM2 degrader shows potent cytotoxicity to MDM2-overexpressing acute lymphoblastic leukemia cells with minimal toxicity to normal cells/tissues
Tao Liu, Lubing Gu, Anna Mui, et al.
European Journal of Medicinal Chemistry
|
May 2, 2023
Synthesis and biological evaluation of dual MDM2/XIAP inhibitors based on the tetrahydroquinoline scaffold
Najah Albadari, Yang Xie, Tao Liu, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
May 21, 2025
Synthesis, <i>in vitro</i> and <i>in silico</i> studies of a novel chrysin-ferrocene Schiff base with potent anticancer activity <i>via</i> G1 arrest, caspase-dependent apoptosis and inhibition of topoisomerase II
Mohammed Khaled Bin Break, Siddique Akber Ansari, Ahmed A Katamesh, et al.
Computational Biology and Chemistry
|
June 20, 2026
Structure-based discovery of PARP15 inhibitors with enhanced binding energetics and stability via quantum refinement for targeted breast cancer therapy
Najah Albadari, Ahmed Alafnan, Mohammed A Almuhayfir, et al.
European Journal of Medicinal Chemistry
|
August 9, 2021
Synthesis and biological evaluation of selective survivin inhibitors derived from the MX-106 hydroxyquinoline scaffold
Najah Albadari, Shanshan Deng, Hao Chen, et al.
Genes & Diseases
|
January 13, 2025
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Wei Wang, Yi Du, Sayantap Datta, et al.
Page
of 2